Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Understand how volatile markets indices signal quick trends and what to watch for when assessing risk and opportunity in real time.
23,576 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Three Buy-rated names are drawing fresh attention in June as Wall Street echoes a defensive, cash-flow bias. AutoZone...
FuelCell Energy surges on a major data-center deal, while Bloom Energy retreats, underscoring a rare divergence in th...
Tom Cruise’s Digger teaser confuses viewers and even investors. This article breaks down what happened, why it matter...
In a volatile 2026 market, retirees are choosing stability over constant client chasing. Experts say build income fir...
Two chipmakers lit up the market in the first half of 2026, but the big question remains: which is the smarter buy no...
Bitcoin stabilizes near $60,000 as July 2026 begins, with traders watching Federal Reserve policy and ETF flows to sh...
Amazon often grabs attention with big growth and bold innovations. This guide helps you pause, assess the real risks,...
A 64-year-old with $1.5 million in retirement assets faces a costly year before Medicare, as ACA premiums and uncover...
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
As 2026 unfolds, retirees weigh early access to Social Security against lifetime income. Early claiming can reduce mo...
A stock delivering a 7% dividend yield and yet slipping 20% year-to-date may seem puzzling. This guide explains how t...